168 related articles for article (PubMed ID: 26998348)
1. The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma.
Lakoma A; Barbieri E; Agarwal S; Jackson J; Chen Z; Kim Y; McVay M; Shohet JM; Kim ES
Cell Death Discov; 2015; 1():15026-. PubMed ID: 26998348
[TBL] [Abstract][Full Text] [Related]
2. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
3. MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.
Fan X; Wang Y; Song J; Wu H; Yang M; Lu L; Weng X; Liu L; Nie G
Cancer Biol Ther; 2019; 20(10):1328-1336. PubMed ID: 31311404
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
Chen K; Xin X; Qiu L; Li W; Guan G; Li G; Qiao M; Zhao X; Hu H; Chen D
Acta Biomater; 2019 Dec; 100():118-131. PubMed ID: 31568878
[TBL] [Abstract][Full Text] [Related]
6. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.
Ciardullo C; Aptullahoglu E; Woodhouse L; Lin WY; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Haematologica; 2019 Dec; 104(12):2429-2442. PubMed ID: 31004033
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
[TBL] [Abstract][Full Text] [Related]
8. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).
Khurana A; Shafer DA
Onco Targets Ther; 2019; 12():2903-2910. PubMed ID: 31289443
[TBL] [Abstract][Full Text] [Related]
9. Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action.
Wang W; Wang X; Rajaei M; Youn JY; Zafar A; Deokar H; Buolamwini JK; Yang J; Foster JH; Zhou J; Zhang R
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291373
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
Zanjirband M; Edmondson RJ; Lunec J
Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
[TBL] [Abstract][Full Text] [Related]
11.
Al-Ghabkari A; Narendran A
Cancer Biother Radiopharm; 2019 May; 34(4):252-257. PubMed ID: 30724592
[No Abstract] [Full Text] [Related]
12. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
13. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
Moreno-Smith M; Lakoma A; Chen Z; Tao L; Scorsone KA; Schild L; Aviles-Padilla K; Nikzad R; Zhang Y; Chakraborty R; Molenaar JJ; Vasudevan SA; Sheehan V; Kim ES; Paust S; Shohet JM; Barbieri E
Clin Cancer Res; 2017 Nov; 23(21):6629-6639. PubMed ID: 28821555
[No Abstract] [Full Text] [Related]
14. Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation.
Zhou Z; Zalutsky MR; Chitneni SK
Mol Pharm; 2021 Oct; 18(10):3871-3881. PubMed ID: 34523337
[TBL] [Abstract][Full Text] [Related]
15.
Wu CE; Chen CP; Pan YR; Jung SM; Chang JW; Chen JS; Yeh CN; Lunec J
Am J Cancer Res; 2022; 12(9):4399-4410. PubMed ID: 36225643
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.
Van Goethem A; Yigit N; Moreno-Smith M; Vasudevan SA; Barbieri E; Speleman F; Shohet J; Vandesompele J; Van Maerken T
Oncotarget; 2017 Aug; 8(34):57047-57057. PubMed ID: 28915653
[TBL] [Abstract][Full Text] [Related]
17. Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib.
Berberich A; Kessler T; Thomé CM; Pusch S; Hielscher T; Sahm F; Oezen I; Schmitt LM; Ciprut S; Hucke N; Ruebmann P; Fischer M; Lemke D; Breckwoldt MO; von Deimling A; Bendszus M; Platten M; Wick W
Clin Cancer Res; 2019 Jan; 25(1):253-265. PubMed ID: 30274984
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.
Zanjirband M; Curtin N; Edmondson RJ; Lunec J
Oncotarget; 2017 Sep; 8(41):69779-69796. PubMed ID: 29050241
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.
Phelps D; Bondra K; Seum S; Chronowski C; Leasure J; Kurmasheva RT; Middleton S; Wang D; Mo X; Houghton PJ
Pediatr Blood Cancer; 2015 Aug; 62(8):1345-52. PubMed ID: 25832557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
